Frank Giles

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

Mark J. Levis, Patrick A. Brown, B. Douglas Smith et al. · Blood · 2006 · 203 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +9

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Daniel J. DeAngelo, Andrew Spencer, Kapil N. Bhalla et al. · Leukemia · 2013 · 138 citations

Medicine, Oncology, Pharmacology +17

Interferon‐alpha up‐regulates bcl‐2 expression and protects B‐CLL cells from apoptosis <i>in vitro</i> and <i>in vivo</i>

Andrew P. Jewell, C. P. Worman, P M Lydyard et al. · British Journal of Haematology · 1994 · 107 citations

Life Sciences, Hematology, Immunology +12

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience

Apostolia M. Tsimberidou, Frank Giles, I. Khouri et al. · Annals of Oncology · 2004 · 52 citations · Full text

Medicine, Hematology, Oncology +8

A Phase 1b Study of Midostaurin (PKC412) in Combination with Daunorubicin and Cytarabine Induction and High-Dose Cytarabine Consolidation in Patients Under Age 61 with Newly Diagnosed De Novo Acute Myeloid Leukemia: Overall Survival of Patients Whose Blasts Have FLT3 Mutations Is Similar to Those with Wild-Type FLT3.

Richard M. Stone, Thomas Fischer, Ronald Paquette et al. · Blood · 2009 · 37 citations

Medicine, Oncology, Pharmacology +17